|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010186,
umls-concept:C0011615,
umls-concept:C0018684,
umls-concept:C0021677,
umls-concept:C0042153,
umls-concept:C0085149,
umls-concept:C0087111,
umls-concept:C0220812,
umls-concept:C0304604,
umls-concept:C0332152,
umls-concept:C0680022,
umls-concept:C1099414,
umls-concept:C1301732,
umls-concept:C1524063,
umls-concept:C1548602,
umls-concept:C1947933
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-5-17
|
|
pubmed:abstractText |
In the United States, pimecrolimus cream and tacrolimus ointment are approved as second-line therapy for short-term and intermittent noncontinuous long-term treatment of atopic dermatitis (AD) in nonimmunocompromised patients aged 2 years or older who have failed to respond adequately to other topical prescription treatments (e.g., topical corticosteroids), or when those treatments are not advisable; pimecrolimus is indicated for mild to- moderate AD and tacrolimus for moderate-to-severe AD. Comparative data on the effects of pimecrolimus versus tacrolimus on AD-related health care utilization and costs among similar patients seen in typical clinical practice are currently unavailable.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1083-4087
|
|
pubmed:author |
pubmed-author:ChangJaneJ,
pubmed-author:DeleaThomas ETE,
pubmed-author:GauseDouglasD,
pubmed-author:GokhaleManjushaM,
pubmed-author:HusseinMohamed AMA,
pubmed-author:JacksonMarkM,
pubmed-author:MakinCharlesC,
pubmed-author:PinkstonPaulP,
pubmed-author:SandmanTimothyT,
pubmed-author:SungJenniferJ,
pubmed-author:VanderpoelJulieJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
349-59
|
|
pubmed:meshHeading |
pubmed-meshheading:17506601-Administration, Topical,
pubmed-meshheading:17506601-Adolescent,
pubmed-meshheading:17506601-Adrenal Cortex Hormones,
pubmed-meshheading:17506601-Adult,
pubmed-meshheading:17506601-Child,
pubmed-meshheading:17506601-Child, Preschool,
pubmed-meshheading:17506601-Dermatitis, Atopic,
pubmed-meshheading:17506601-Female,
pubmed-meshheading:17506601-Health Expenditures,
pubmed-meshheading:17506601-Humans,
pubmed-meshheading:17506601-Insurance Claim Review,
pubmed-meshheading:17506601-Male,
pubmed-meshheading:17506601-Managed Care Programs,
pubmed-meshheading:17506601-Pharmaceutical Services,
pubmed-meshheading:17506601-Tacrolimus,
pubmed-meshheading:17506601-United States
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus.
|
|
pubmed:affiliation |
Policy Analysis Inc., Brookline, Massachusetts 02445, USA. tdelea@pai2.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
